# Ionizing Radiation Increases Death Receptor 5 (DR5)-Mediated Cell Death, but Not Death Receptor 4 (DR4)-Mediated Cell Death in 3D Tumor Spheroids

**Authors:** Fengzhi Suo, Xinyu Zhou, Abel Soto-Gamez, Fleur B. Nijdam, Rita Setroikromo, Wim J. Quax

PMC · DOI: 10.3390/ijms26104635 · International Journal of Molecular Sciences · 2025-05-13

## TL;DR

Ionizing radiation combined with TRAIL increases DR5-mediated cell death in 3D tumor spheroids but not DR4-mediated death.

## Contribution

The study reveals that radiation enhances DR5-specific TRAIL-induced cell death in 3D spheroids but not DR4-specific death.

## Key findings

- Ionizing radiation upregulates DR4 and DR5 in 2D cancer cells.
- In 3D spheroids, radiation enhances DR5-mediated TRAIL-induced cell death but not DR4-mediated death.
- The lack of DR4 overexpression in 3D spheroids explains the differential effect.

## Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potential therapeutic for cancer patients due to its tumor specificity. However, TRAIL resistance in cancer cells limits its development in clinical trials. Given that ionizing radiation (IR) is an established method of inducing DNA damage for cancer during radiotherapy, we applied a combined treatment of IR and TRAIL. Our study shows that the combination treatment of IR and TRAIL promoted cell death due to IR upregulating both DR4/DR5 receptors on the surface of human lung carcinoma cell line H460 and human colon cancer cell line DLD-1 2D cells. However, when cultured as 3D spheroids, we observed that IR enhanced DR5-specific TRAIL-induced cell death but attenuated DR4-specific TRAIL-induced cell death. The immunohistochemical analysis of 3D cell spheroid sections indicates that it is due to a lack of DR4 overexpression by IR. Our findings elucidate a potential explanation for the failure of the combination treatment of radiotherapy with TRAIL in clinical trials. Additionally, our findings advocate the potential efficacy of employing DR5-specific TRAIL in combination with radiation as a promising therapeutic strategy.

## Linked entities

- **Genes:** HLA-DRB4 (major histocompatibility complex, class II, DR beta 4) [NCBI Gene 3126], TNFRSF10B (TNF receptor superfamily member 10b) [NCBI Gene 8795], TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743]
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TNFRSF10B (TNF receptor superfamily member 10b) [NCBI Gene 8795] {aka CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2}, TNFRSF10A (TNF receptor superfamily member 10a) [NCBI Gene 8797] {aka APO2, CD261, DR4, TRAILR-1, TRAILR1}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}
- **Diseases:** lung carcinoma (MESH:D008175), Tumor (MESH:D009369), colon cancer (MESH:D015179)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** DLD-1 2D — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_V012), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12110968/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12110968/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12110968/full.md

---
Source: https://tomesphere.com/paper/PMC12110968